[Business Wire] - NEW YORK----The Rosen Law Firm today announced that it has commenced an investigation into allegations that AspenBio Pharma, Inc. violated the federal securities laws by issuing false and misleading statements to investors about its product candidate AppyScore.

[GlobeNewswire] - RESEARCH TRIANGLE PARK, N.C. -- Icagen, Inc. today announced that its Board of Directors has determined to proceed with the one-for-eight reverse stock split previously approved by its stockholders.

[at MarketWatch] - Celldex Therapeutics shares plunge in early trading after the biotech group announces that Pfizer Inc. was pulling out of a pact to develop Celldex's cancer vaccine CDX-110.

[AP] - Pfizer Inc. is pulling out of a development deal with Celldex Therapeutics Inc. on a potential brain cancer drug, saying it is not a strategic priority, Celldex said.

[PR Newswire] - Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut , effective November 1, 2010. Celldex and Pfizer Vaccines LLC entered into a global development and commercialization agreement in April 2008 for rindopepimut, an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III in patients with Glioblastoma Multiforme .

[PR Newswire] - LifeVantage Corporation , the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE.  The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice.  That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.  Protandim®, a patented dietary supplement comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes.